Drug Trial Radar · NCT01626066
Cathepsin Activatable Fluorescent Probe
Last checked: Nov 19, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Jun 2012
Primary completion
Aug 2014
Study completion Aug 2015
Sponsor
- Lead sponsor
- David KirschAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Society of Clinical Oncology
- First posted
- Jun 22, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Real-time detection of cancer cells during surgical removal of a tumor is important. Currently when tissue is removed at the time of surgery, the removed tissue goes to pathology when the margins (edges of the tissue) are examined to see if cancer cells are present. This may take a few to several days. Patients tissue with positive (cancer cells present) margins may require additional therapies including surgery. The purpose of this study is to determine a safe dose of a new imaging agent (LUM015), like a fluorescent contrast agent or dye, that will show in the tumor area during surgery and may help facilitate visualization of tumor for its removal.
Conditions
- Sarcoma
- Soft Tissue Sarcoma
- Breast Cancer
Interventions
LUM015Drug
LUM015 assigned dose given once by IV push
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose of LUM015 in mgTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.